Maven Securities LTD Invests $4.62 Million in Roivant Sciences Ltd. (NASDAQ:ROIV)

Maven Securities LTD acquired a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 400,000 shares of the company’s stock, valued at approximately $4,616,000. Maven Securities LTD owned about 0.05% of Roivant Sciences at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of ROIV. Clearbridge Investments LLC boosted its holdings in shares of Roivant Sciences by 51.3% during the 2nd quarter. Clearbridge Investments LLC now owns 1,860,536 shares of the company’s stock valued at $19,666,000 after acquiring an additional 630,712 shares during the last quarter. Cetera Advisors LLC purchased a new stake in Roivant Sciences in the first quarter worth approximately $758,000. Point72 Asset Management L.P. grew its position in Roivant Sciences by 40.1% in the 2nd quarter. Point72 Asset Management L.P. now owns 647,126 shares of the company’s stock worth $6,840,000 after purchasing an additional 185,226 shares during the period. Exchange Traded Concepts LLC purchased a new stake in Roivant Sciences during the 3rd quarter valued at $2,267,000. Finally, SG Americas Securities LLC bought a new position in shares of Roivant Sciences during the 2nd quarter valued at $472,000. 64.76% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several brokerages recently commented on ROIV. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. HC Wainwright restated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday, November 13th. Finally, Bank of America upped their price target on shares of Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a research report on Wednesday, September 11th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.93.

Insider Activity at Roivant Sciences

In related news, CEO Matthew Gline sold 1,983,257 shares of Roivant Sciences stock in a transaction that occurred on Monday, September 23rd. The shares were sold at an average price of $11.79, for a total transaction of $23,382,600.03. Following the transaction, the chief executive officer now directly owns 17,870,543 shares of the company’s stock, valued at $210,693,701.97. This trade represents a 9.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.89, for a total value of $2,972,500.00. Following the completion of the transaction, the chief accounting officer now owns 209,322 shares in the company, valued at $2,488,838.58. This trade represents a 54.43 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 3,677,309 shares of company stock worth $43,283,184. Company insiders own 7.90% of the company’s stock.

Roivant Sciences Trading Down 2.9 %

Shares of Roivant Sciences stock opened at $12.12 on Wednesday. The firm has a market cap of $8.82 billion, a PE ratio of 2.15 and a beta of 1.25. Roivant Sciences Ltd. has a 12 month low of $9.48 and a 12 month high of $13.06. The stock has a 50 day moving average of $11.78 and a 200 day moving average of $11.39.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.